全文获取类型
收费全文 | 209篇 |
免费 | 9篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 9篇 |
基础医学 | 19篇 |
口腔科学 | 3篇 |
临床医学 | 14篇 |
内科学 | 44篇 |
皮肤病学 | 7篇 |
神经病学 | 21篇 |
特种医学 | 14篇 |
外科学 | 30篇 |
综合类 | 1篇 |
预防医学 | 4篇 |
眼科学 | 12篇 |
药学 | 17篇 |
肿瘤学 | 28篇 |
出版年
2022年 | 1篇 |
2021年 | 7篇 |
2019年 | 4篇 |
2018年 | 9篇 |
2017年 | 4篇 |
2016年 | 7篇 |
2015年 | 7篇 |
2014年 | 6篇 |
2013年 | 8篇 |
2012年 | 9篇 |
2011年 | 12篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 10篇 |
2007年 | 15篇 |
2006年 | 2篇 |
2005年 | 18篇 |
2004年 | 8篇 |
2003年 | 13篇 |
2002年 | 21篇 |
2001年 | 11篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1998年 | 5篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1988年 | 2篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1982年 | 2篇 |
1981年 | 3篇 |
1980年 | 1篇 |
排序方式: 共有224条查询结果,搜索用时 15 毫秒
1.
Shouhei Nagaoka Mitsuyuki Nakamura Akiko Senuma Akiko Sekiguchi 《Nihon Rinshō Men'eki Gakkai kaishi》2005,28(6):389-397
The efficacy and safety of MTX in active RA were evaluated based on patient medical records. The study population consisted of 460 patients with active RA who had received no prior MTX therapy and started it at our hospital between August 1998 and December 2003 (80 men and 380 women with a mean age of 59.3 years). After 24 weeks of MTX therapy, 61.3% of patients showed a 20% improvement, and 30.4% achieved a 50% improvement according to the ACR criteria. The cumulative rate of patients who continued MTX therapy for 48 weeks was 0.567. During the observation period, 260 patients (56.5%) experienced 304 adverse reactions. 52 patients (11.3%) discontinued treatment because of adverse reactions, and 10 patients (2.2%) died. The adverse reactions that occurred in at least 1% of patients were: abnormal hepatic function (31.7%), infection (6.1%), gastrointestinal symptoms (5.0%), stomatitis (3.9%), hematological abnormalities (3.5%), fracture (3.5%), malignant tumor (2.6%), interstitial pneumonia (2.0%), cerebrovascular or cardiovascular disorder (2.0%), headache (1.7%), eruption (1.3%), and alopecia (1.1%). Adverse reactions were more common in the elderly and patients with advanced stage disease. This study reaffirms the therapeutic benefit of MTX, but suggests that careful monitoring is of great importance. 相似文献
2.
Inhibition of p38MAP kinase suppresses fibrotic reaction of retinal pigment epithelial cells 总被引:3,自引:0,他引:3
3.
Iku Utsunomiya Kenji Tani Wanghua Gong Joost J. Oppenheim Ji Ming Wang 《European journal of immunology》1997,27(6):1406-1412
The C-C chemokine RANTES, a T lymphocyte chemoattractant, is considered an important mediator of inflammation, allergy, and host defense against HIV-1 infection. In this study, we investigated the modulation of binding of RANTES to T lymphocytes. Human peripheral blood CD3+ T cells, when freshly isolated from buffy-coat blood, expressed a considerable number of high-affinity binding sites for RANTES. These cells also showed significant chemotactic migration in response to RANTES in vitro. After 6–15 h incubation at 37°C, the binding of RANTES, but not of macrophage inflammatory protein-1α (MIP-1α) or of monocyte chemotactic protein-3 (MCP-3), consistently increased. Scatchard analyses indicated that the number of binding sites for RANTES increased about threefold by 15 h without any change in the affinity. The increase in RANTES binding was no longer detected by 24 h. This increase in the specific binding was mainly attributable to CD4+ T cells and was not associated with increased chemotactic activity of these cells in response to RANTES. Incubation with anti-CD3 antibody for 15 h markedly reduced the binding capability of T cells for RANTES and was associated with decreased chemotactic activity. On the other hand, when T cells were incubated with interleukin-2 (IL-2) for 1 week, the specific binding for all three C-C chemokines, RANTES, MIP-1α, and MCP-3 was markedly increased in comparison to cells cultured in the absence of IL-2. These results suggest that the expression of binding sites on T cells for RANTES is differentially modulated, indicating the existence of novel receptors for RANTES that do not bind MIP-1α. 相似文献
4.
Obuse C Yang H Nozaki N Goto S Okazaki T Yoda K 《Genes to cells : devoted to molecular & cellular mechanisms》2004,9(2):105-120
CENP-A, a centromere-specific histone H3, is conserved throughout eukaryotes, and formation of CENP-A chromatin defines the active centromere region. Here, we report the isolation of CENP-A chromatin from HeLa interphase nuclei by chromatin immunoprecipitation using anti-CENP-A monoclonal antibody, and systematic identification of its components by mass spectrometric analyses. The isolated chromatin contained CENP-B, CENP-C, CENP-H, CENP-I/hMis 6 and hMis 12 as well as CENP-A, suggesting that the isolated chromatin may represent the centromere complex (CEN-complex). Mass spectrometric analyses of the CEN-complex identified approximately 40 proteins, including the previously reported centromere proteins and the proteins of unknown function. In addition, we unexpectedly identified a series of proteins previously reported to be related to functions other than chromosome segregation, such as uvDDB-1, XAP8, hSNF2H, FACTp180, FACTp80/SSRP1, polycomb group proteins (BMI-1, RING1, RNF2, HPC3 and PHP2), KNL5 and racGAP. We found that uvDDB-1 was actually localized to the centromeric region throughout cell cycle, while BMI-1 was transiently co-localized with the centromeres in interphase. These results give us new insights into the architecture, dynamics and function of centromeric chromatin in interphase nuclei, which might reflect regulation of cell proliferation and differentiation. 相似文献
5.
Suda A Nagaoka S Ohono S Ideguchi H Soga T Ishigatsubo Y 《Modern rheumatology / the Japan Rheumatism Association》2008,18(6):609-614
We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a
first-line DMARD in the treatment of rheumatoid arthritis (RA). We conducted a retrospective cohort study and reviewed medical
records of 86 patients with active RA who began to receive bucillamine at Yokohama Minami Kyosai Hospital between January
1998 and July 2004. The efficacy of treatments was compared based on rates of achievement of 20, 50, and 70% improvement in
ACR core set 6 months after initiation of the therapy. In the group administered bucillamine as a first-line DMARD (18 patients),
44.4, 22.2, and 11.1% of patients achieved ACR 20, 50, 70, respectively, while 56.5, 34.1, and 19.5% achieved ACR 20, 50,
70, respectively, in the group administered bucillamine following switching from MTX (46 patients), and 53.3, 33.3, and 13.3%
achieved ACR 20, 50, and 70, respectively, in the group administered bucillamine following switching from Sulfasalazine (SSZ)
(15 patients). The rates of achievements of ACR 20, 50, 70 did not differ statistically between the three groups and there
was no increase in risk of serious adverse effects related to previous DMARDs. The usefulness of bucillamine as a second-line
DMARD was demonstrated. 相似文献
6.
Takeshi Asano Hidehiko Narazaki Kiyohiko Kaizu Shouhei Matsukawa Yuki Takema‐Tochikubo Shuichi Fujii Nobuyuki Saitoh Kunihiko Mashiko Osamu Fujino 《Pediatrics international》2015,57(5):988-990
Although thrombotic thrombocytopenic purpura (TTP) is rare, early diagnosis and treatment are important for decreasing the mortality rate. Acquired vitamin B12 deficiency is frequently overlooked because of its rarity in developed countries, particularly in children and adolescents. The hematological changes in vitamin B12 deficiency present as megaloblastic anemia, increased lactate dehydrogenase, vasoconstriction, increased platelet aggregation, and abnormal activation of the coagulation followed by microangiopathy as well as neutropenia and thrombocytopenia. We report herein the case of a 15‐year‐old girl who had been neglected, which might have caused pseudo‐TTP through malnutrition, particularly vitamin B12 deficiency. When we encounter cases of TTP in children, clinicians must be aware of the possibility of malnutrition, particularly with vitamin B12 deficiency, even in developed countries, and investigate the cause of malnutrition including neglect. 相似文献
7.
Bone lesions in elderly multiple myeloma 总被引:2,自引:0,他引:2
Umeda M Adachi Y Tomiyama J Takasaki M Shin K Mori M Tsutsumi H Murai Y Mutoh Y Tomoyasu S Kawato M Nakamura N Metori S Yamaguchi H;Society for Geriatric Hematology 《Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics》2002,39(6):631-638
We investigated the incidence of bone lesions in elderly cases of multiple myeloma (MM) and the course of those lesions, and also evaluated the relationships of skeletal symptoms with prognostic factors, and prognosis. The subjects were 146 patients, aged 65 years or more (median age 74, range 65-97 year), who were admitted to 11 institutions between January, 1988 and December, 1997. They consisted of 64 men and 82 women. The disease type was IgG type in 88 patients, IgA type in 37 patients, Bence-Jones (BJ) type in 17 patients, IgD type in three patients, and non-secretory type in one patient. Bone lesions in elderly MM patients were compared with those in 65 non-elderly MM patients. Skeletal symptoms were noted in 104 patients, and bone pain in 75 patients at the time of diagnosis. The bone lesions were evaluated as only osteolytic lesions in 26 patients, osteolytic lesions + osteoporosis in 23 patients, only osteoporosis in 2 patients and pathologic bone fractures in 53 patients. The occurrence rate of osteoporosis plus osteolytic lesion was higher in elderly patients (63.5%) than that in non-elderly patients (NE-MM group) (28.3%) (p < 0.0001). The bone lesions were most often observed in lumbar vertebrae (58.7%), cranial bone (56.7%), thoracic vertebrae (40.4%) and ribs (27.9%). The occurrence rate of bone lesion in lumbar vertebrae was higher in elderly patients (58.7%) than that in non-elderly patients (22.6%) (p < 0.0001). The life activities were limited in 71 patients because of the bone lesions. The relationship between the prognostic factors of MM and bone lesions was evaluated. There was a significant difference in the serum Ca level between patients with and without bone pain (P < 0.0001) and between those with and without pathologic bone fracture (P < 0.01). There was a significant difference in the appearance rate of plasma cells in the bone marrow between the patients with and without bone lesions (P < 0.05), between those with and without bone pain (P < 0.01), and between those with and without pathologic fracture (P < 0.05). There was a significant difference in the serum beta 2-microglobulin level between the patients with and without bone pain, and between those with and without pathologic fracture. There were no significant differences in survival times between elderly MM patients with and without bone lesions, bone pain and pathological bone fractures, while significant differences of survival times were found between non-elderly MM patients with and without bone lesions, bone pain and pathological bone fractures (P < 0.05, each). These data suggest that there are some differences in bone lesions between elderly and non-elderly MM patients. 相似文献
8.
Iku Kamitani Takeshi Saito Hiroki Yokoyama Aya Nakano Hiroto Ishii Susumu Tanoue Daiki Hattori Sayaka Oshima Shoko Ishii Tadahiro Gunji Ryoko Fukushima Atsushi Katsube Takaki Shimada Kaichi Nishiwaki Nobuaki Dobashi Shingo Yano 《Journal of infection and chemotherapy》2021,27(4):639-641
The FMS-related tyrosine kinase 3 (FLT3) internal tandem duplication mutations (FLT3-ITD) positive acute myeloid leukemia (AML) is a disease with a dismal outcome. Gilteritinib is a second-generation FLT3 inhibitor with activity against ITD and high affinity toward the FLT3 receptor, thereby showing therapeutic potential for relapsed/refractory FLT3-mutated AML. Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA) identical sibling donor was performed in a 38-year-old Japanese male with FLT3-ITD positive AML. Neutrophil engraftment (>0.5 × 109/L) was achieved on day 16, and bone marrow remission was revealed on day 32. The patient's AML relapsed hematologically four months after BMT and was resistant to salvage chemotherapy. Gilteritinib was administered and the patient achieved non-remission but ‘stable disease’ status according to the response criteria. During administration, liver damage was observed but controllable. The patient received cord blood transplantation (CBT) as the second hematopoietic stem cell transplantation (HSCT) three months after relapse and achieved second remission. There was no evidence of recurrence of AML four months after CBT. This case demonstrates that gilteritinib can control FLT3-ITD positive AML that relapsed early after initial HSCT and can bridge to second HSCT. 相似文献
9.
Uno Takehiro Misaki Kouichi Futami Kazuya Nambu Iku Yoshikawa Akifumi Kamide Tomoya Uchiyama Naoyuki Nakada Mitsutoshi 《Neurological sciences》2022,43(3):1849-1857
Neurological Sciences - Although bleb formation increases the risk of rupture of intracranial aneurysms, previous computational fluid dynamic (CFD) studies have been unable to identify robust... 相似文献
10.
Takenori Yamauchi Shouhei Takeuchi Naoki Maehara Yoshiki Kuroda 《Environmental health and preventive medicine》2014,19(4):265-270